On September 13, Hansen Pharmaceuticals (Hausen Pharmaceuticals, 3692.
HK) announced that ibrexafungerp, which has rights in the Greater China region, has submitted a Phase III clinical trial application to the National Medical Products Administration (NMPA) for the treatment of mold.
Sexual vaginitis
.
As early as February 11 this year, Hansen Pharmaceuticals announced that it had entered into an exclusive license and cooperation agreement with SCYNEXIS, Inc.
(NASDAQ: SCYX)
.
According to the license agreement, the licensee Hansen Pharmaceuticals will obtain the exclusive license of SCYNEXIS to research, develop and commercialize ibrexafungerp in the People's Republic of China (including Hong Kong, Macau and Taiwan)
.
As a consideration for the exclusive franchise, the licensee agreed to pay SCYNEXIS a down payment of US$10 million plus potential milestone payments and commissions
.
On June 2, 2021, ibrexafungerp (trade name: BREXAFEMME) was approved by the U.
S.
Food and Drug Administration (FDA)
.
